3-benzyl-5-methyl-1,2,4-oxadiazole | 55152-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzyl-5-methyl-1,2,4-oxadiazole
• 英文别名: 3-benzyl-5-methyl-[1,2,4]oxadiazole；3-Benzyl-5-methyl-[1,2,4]oxadiazol；1,2,4-Oxadiazole, 5-methyl-3-(phenylmethyl)-
• CAS: 55152-22-2
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD18801016
• 分子量: 174.202
• InChiKey: JKJLACIVOOYBSE-UHFFFAOYSA-N

物化性质

• 沸点：
  262 °C
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-乙酰-DL-苯丙氨酸 在 甲醇 、 三乙胺 作用下， 反应 2.0h， 生成 3-benzyl-5-methyl-1,2,4-oxadiazole
  参考文献：
  名称：

  Chow, Yuan L.; Polo, Joel S., Journal of the Chemical Society. Perkin transactions II, 1986, p. 727 - 734

  摘要：

  DOI：

文献信息

• Cyanothiophene derivatives, compositions containing such compounds and methods of use
  申请人：——

  公开号：US20040097552A1

  公开（公告）日：2004-05-20

  The present invention addresses substituted cyanothiophene derivatives of the formula I: 1 as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

  本发明涉及式I的取代氰基噻吩衍生物，以及含有这种化合物的组合物和治疗方法。本发明中的化合物是胰高血糖素拮抗剂。这些化合物阻断了胰高血糖素在其受体上的作用，从而降低血浆葡萄糖水平，提供糖尿病的治疗。
• DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
  申请人：Sanofi

  公开号：US20130137691A1

  公开（公告）日：2013-05-30

  The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a —CH— group; X1 represents a nitrogen atom or a —CH═CH— group; X2 represents an oxygen atom or a nitrogen atom; X3 represents an oxygen atom or a nitrogen atom; one of X1, X2, X3 being other than a nitrogen atom, X2 and X3 not being an oxygen atom at the same time; R1, R2 are absent or represent, (i) independently of one another, a hydrogen atom or a (C1-C4)alkyl group, (ii) R1 and R2 may form, with the carbon atom to which they are attached, a —(C3-C10)cycloalkyl- group; Y represents a —(C3-C10)cycloalkyl-, aryl or aryloxy group, said groups being optionally substituted with one or more substituents chosen from a halogen atom or a (C1-C6)alkoxy group; Z1 is absent or represents an —NH— function; Z2 and Z3 are as defined in the description. The invention also relates to a process for preparing compounds of formula (I), compositions containing them and their application in therapeutics.

  本发明涉及公式（I）的化合物： 其中： n等于0或1； D代表氧原子或键； W代表氮原子或—CH—基团； X1代表氮原子或—CH═CH—基团； X2代表氧原子或氮原子； X3代表氧原子或氮原子； X1、X2、X3中的一个不是氮原子，X2和X3同时不是氧原子； R1，R2不存在或代表（i）彼此独立的氢原子或（C1-C4）烷基，（ii）R1和R2可以与它们附着的碳原子形成—（C3-C10）环烷基-基团； Y代表—（C3-C10）环烷基-、芳基或芳氧基团，这些基团可以选择性地被一个或多个卤素原子或（C1-C6）烷氧基置换； Z1不存在或代表—NH—功能； Z2和Z3如本说明中所定义。 本发明还涉及制备公式（I）的化合物的方法、含有它们的组合物以及它们在治疗学中的应用。
• DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST
  申请人：Linders Joannes Theodorus Maria

  公开号：US20110112111A1

  公开（公告）日：2011-05-12

  The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. The present invention also relates to novel DGAT inhibitors. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicament of said compounds.

  本发明涉及一种DGAT抑制剂和过氧化物酶体增殖激活受体（PPAR）激动剂或其前药的组合物。本发明还涉及制备这种组合物的方法，以及包含该组合物的制药组合物和该组合物作为药物的用途。本发明还涉及新型的DGAT抑制剂。本发明还涉及制备这种化合物的方法，以及包含该化合物的制药组合物和该化合物作为药物的用途。
• INDANE COMPOUNDS AS CCR5 ANTAGONISTS
  申请人：YOUNGMAN Michael

  公开号：US20090187021A1

  公开（公告）日：2009-07-23

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式（I）的化合物或其药学上可接受的衍生物，用于治疗CCR5相关的疾病和障碍，例如，用于抑制HIV复制，预防或治疗HIV感染，并用于治疗由此导致的获得性免疫缺陷综合症（AIDS）。
• Durio; Sburlati, Gazzetta Chimica Italiana, 1932, vol. 62, p. 1035,1038
  作者：Durio、Sburlati

  DOI：——

  日期：——